Drug Profile
Research programme: therapeutic monoclonal antibodies - Kymab/Novo Nordisk
Latest Information Update: 14 Apr 2021
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 09 Apr 2021 Kymab has been acquired by Sanofi
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Denmark (Parenteral)
- 22 Apr 2013 Early research in Undefined indication in Denmark (Parenteral)